



Rosa Herrera  
Fleishman Hillard  
404.739.0153  
[herrerar@fleishman.com](mailto:herrerar@fleishman.com)

**FOR IMMEDIATE RELEASE**

**ALIMERA SCIENCES NAMES PHIL TRACY CHAIRMAN OF THE BOARD**

ATLANTA (March 7, 2005) – Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, today named Phil Tracy, J.D., chairman of the company’s board of directors.

Highly respected in the pharmaceutical and venture capital industries, Tracy served from 1989 to 1995 as the president and CEO of Burroughs Wellcome Co., a major pharmaceutical company with \$1.2 billion in sales and 5,000 employees, until its 1995 merger with Glaxo Inc. Tracy has been a venture partner with Intersouth Partners since 1997 and has worked with dozens of life sciences companies in their growth and development.

“We are privileged to have such a distinguished professional at the helm of Alimera Sciences’ board. Phil’s experience and accomplishments in both pharmaceutical development and venture funding will greatly contribute to Alimera’s growth and success,” said Dan Myers, CEO of Alimera Sciences.

Tracy joined the Alimera Sciences board of directors in July 2004. He also serves on the board of the Burroughs Wellcome Fund and the Peace College board of trustees.

**About Alimera Sciences Inc.**

Alimera Sciences Inc. specializes in the development and commercialization of over-the-counter and prescription ophthalmology pharmaceuticals. Founded by an executive team with extensive development and revenue growth expertise, Alimera Sciences’ products address underserved and overlooked areas of the ophthalmic market. In August 2004, Alimera Sciences unveiled *Soothe*<sup>™</sup>, the market’s first multi-dose, emollient-based artificial tear product.

[www.alimerasciences.com](http://www.alimerasciences.com)

###